


**NEUREX**  
MEETING/WORKSHOP

**NOVEMBER**  
22<sup>TH</sup>, 2021  
**ILLKIRCH**

**VENUE**  
**7HOTEL**  
550 BD SÉBASTIEN BRANT  
67400 ILLKIRCH - FRANCE  
SANITARY PASS MANDATORY

**ORGANIZERS**  
**DR. FRANÇOISE DANTZER**  
& **PR. D. BAGNARD**



— **PROJECT INTERNEURON** —

Program Interreg V Upper Rhine «Transcending borders with every project», Neurex, Médalis, BioValley France, CNRS, Université de Strasbourg, Région Grand Est, Département du Bas-Rhin, Département du Haut-Rhin, Eurométropole Strasbourg, Hôpitaux Universitaires de Strasbourg, Bernstein Center Freiburg, Klinik für Psychiatrie und Psychotherapie Freiburg, Neurozentrum Freiburg, Universität Freiburg, Universität Basel, Universitäre Psychiatrische Kliniken Basel, Kanton Aargau, Kanton Basel-Landschaft, Confédération suisse.

# NEW APPROACHES TO TACKLE GLIOBLASTOMA RESISTANCE

MONDAY, NOVEMBER 22<sup>TH</sup>, 2021

Program and registration at [www.neurex.org](http://www.neurex.org)

09.30  
09.55

WELCOME OF PARTICIPANTS  
WORKSHOP SHORT INTRODUCTION

10.00

**SESSION 1**

Chaired by Dr Françoise Dantzer

10.00

**Romane AUVERGNE** — (ICANS)

"Targeting cancer stem cells and their associated microenvironment: clinical relevance for glioblastoma treatment"

10.30

**Dominique BAGNARD** — (IMS)

"Peptide-based targeting of Glioblastoma cells and microglia: towards a new therapeutic approach?"

11.00

**Laurent DAEFFLER** — (IPHC)

"Combination of proton radiations and oncolytic viruses to eradicate cancers, including glioblastomas and pancreatic adenocarcinomas"

11.30

**Samuel VALABLE** — (CNRS)

"Detection and strategies to overcome hypoxia-induced radioresistance in glioblastoma"

12.00

LUNCH

13.30

**SESSION 2**

Chaired by Pr Dominique Bagnard

13.30

**Monique DONTENWILL** — (CNRS)

"Molecular states of glioblastoma to define therapeutic targets"

14.00

**Françoise DANTZER** — (BSC, CNRS)

"Targeted therapy for brain tumours: challenges and perspectives for PARPs"

14.30

**Thomas DAUBON** — (BioDynaMit team, CNRS)

"Better understanding glioblastoma intratumor heterogeneity to target"

15.00

**Claire LEPINOUX-CHAMBAUD** — (Gliocure)

"Gliocure: preclinical, pharmaceutical and pharmacological development of drug candidates in neuro-oncology"

15.30

**Maximilien VERMANDEL** — (Hemerion Therapeutics)

"Hemerion Therapeutics: an innovative Drug/Device combo for the surgical management of Glioblastoma"

16.00

COFFEE BREAK

16.30

ROUND TABLE: models, hierarchy of targets, combination therapy

17.30

END OF THE WORKSHOP

Interneuron



ims  
INSTITUT DU MÉDICAMENT  
DE STRASBOURG